JP2016516808A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516808A5 JP2016516808A5 JP2016508288A JP2016508288A JP2016516808A5 JP 2016516808 A5 JP2016516808 A5 JP 2016516808A5 JP 2016508288 A JP2016508288 A JP 2016508288A JP 2016508288 A JP2016508288 A JP 2016508288A JP 2016516808 A5 JP2016516808 A5 JP 2016516808A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- bcl
- activity
- amount
- downregulates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 18
- 230000000694 effects Effects 0.000 claims 12
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 4
- 230000003902 lesion Effects 0.000 claims 4
- 208000019693 Lung disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical group C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 claims 1
- 101710157567 Cyclin-dependent kinase inhibitor 1 Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 229940123457 Free radical scavenger Drugs 0.000 claims 1
- 102000011782 Keratins Human genes 0.000 claims 1
- 108010076876 Keratins Proteins 0.000 claims 1
- 229940124091 Keratolytic Drugs 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 230000003712 anti-aging effect Effects 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 239000013043 chemical agent Substances 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000002085 irritant Substances 0.000 claims 1
- 230000001530 keratinolytic effect Effects 0.000 claims 1
- 230000003020 moisturizing effect Effects 0.000 claims 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical group C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 claims 1
- 229950004847 navitoclax Drugs 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 230000036573 scar formation Effects 0.000 claims 1
- 210000002374 sebum Anatomy 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361814286P | 2013-04-21 | 2013-04-21 | |
| US61/814,286 | 2013-04-21 | ||
| PCT/IL2014/050358 WO2014174511A1 (en) | 2013-04-21 | 2014-04-13 | Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016516808A JP2016516808A (ja) | 2016-06-09 |
| JP2016516808A5 true JP2016516808A5 (OSRAM) | 2017-05-25 |
Family
ID=50877543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016508288A Pending JP2016516808A (ja) | 2013-04-21 | 2014-04-13 | Ｂｃｌ−ｘＬおよび／またはＢｃｌ−ｗの活性および／または量を下方制御するための薬剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160122758A1 (OSRAM) |
| EP (1) | EP2988767A1 (OSRAM) |
| JP (1) | JP2016516808A (OSRAM) |
| CN (1) | CN105377289A (OSRAM) |
| BR (1) | BR112015026702A2 (OSRAM) |
| CA (1) | CA2909380A1 (OSRAM) |
| MX (1) | MX2015014582A (OSRAM) |
| RU (1) | RU2015149680A (OSRAM) |
| WO (1) | WO2014174511A1 (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009085216A2 (en) | 2007-12-20 | 2009-07-09 | Squicor | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease |
| WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| US20140335074A1 (en) | 2011-12-13 | 2014-11-13 | Buck Institute For Research On Aging | Methods for improving medical therapies |
| US20150064137A1 (en) | 2012-04-17 | 2015-03-05 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| US10279018B2 (en) | 2012-12-03 | 2019-05-07 | Unity Biotechnology, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US9993472B2 (en) | 2014-01-28 | 2018-06-12 | Unity Biotechnology, Inc. | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| WO2015171591A1 (en) | 2014-05-05 | 2015-11-12 | Board Of Trustees Of The University Of Arkansas | COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS |
| EP3177144A4 (en) | 2014-07-22 | 2018-01-24 | Bioventures, LLC. | Compositions and methods for selectively depleting senescent cells |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| HK1249030A1 (zh) * | 2015-02-06 | 2018-10-26 | Unity Biotechnology, Inc. | 化合物及在治疗衰老相关病症中的用途 |
| WO2016135732A1 (en) * | 2015-02-26 | 2016-09-01 | Yeda Research And Development Co. Ltd. | Method of promoting hair growth |
| WO2016185481A2 (en) | 2015-05-20 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Method of targeting senescent cells |
| WO2017002120A1 (en) * | 2015-07-02 | 2017-01-05 | Yeda Research And Development Co. Ltd. | Selective inhibitors of senescent cells and uses thereof |
| WO2017101851A1 (en) | 2015-12-18 | 2017-06-22 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
| KR102447884B1 (ko) | 2016-04-21 | 2022-09-27 | 바이오벤처스, 엘엘씨 | 항-세포자멸적 bcl-2 계열 단백질의 열화를 유도하는 화합물 및 이의 용도 |
| KR102011105B1 (ko) * | 2017-02-22 | 2019-08-14 | 국립암센터 | 고시폴 및 펜포르민을 유효성분으로 포함하는 췌장암 예방 및 치료용 약학적 조성물 |
| US20200354336A9 (en) | 2017-08-11 | 2020-11-12 | Unity Biotechnology, Inc. | Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells |
| WO2019033119A1 (en) * | 2017-08-11 | 2019-02-14 | Unity Biotechnology, Inc. | TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
| US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
| US10689416B2 (en) | 2017-12-30 | 2020-06-23 | Unity Biotechnology, Inc. | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
| CA3088253A1 (en) | 2018-01-22 | 2019-07-25 | Bioventures, Llc | Bcl-2 proteins degraders for cancer treatment |
| US10738042B2 (en) | 2018-04-30 | 2020-08-11 | Unity Biotechnology, Inc. | Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| CN117866015A (zh) | 2018-04-30 | 2024-04-12 | 联合生物科技公司 | 一种临床管理中使用的化合物及其用途 |
| CA3056878C (en) | 2018-04-30 | 2021-03-30 | Unity Biotechnology | Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| US12084423B2 (en) | 2018-05-18 | 2024-09-10 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| US10717722B2 (en) | 2018-06-13 | 2020-07-21 | Unity Biotechnology, Inc. | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| CN109387493B (zh) * | 2018-09-21 | 2020-12-22 | 山东大学 | 一种pH响应型自辅因子DNAzyme ZnO纳米探针及其制备方法与应用 |
| EP3906930A4 (en) * | 2018-12-05 | 2022-08-24 | Nitto Denko Corporation | RNAI MOLECULE FOR TREATMENT OF CANCER |
| IL275186A (en) | 2020-06-07 | 2022-01-01 | Yeda Res & Dev | Human antibodies against grp94 and uses |
| CN111973578A (zh) * | 2020-08-03 | 2020-11-24 | 天津医科大学 | C188-9、Venetoclax、Bumetanide在纤维化疾病药物中的应用 |
| CN112294962B (zh) * | 2020-11-13 | 2023-06-06 | 上海长海医院 | Bcl-2及bcl-xl抑制剂在瘢痕治疗中的应用 |
| AU2021411103B2 (en) * | 2020-12-28 | 2025-04-24 | 1E Therapeutics, Ltd. | P21 mrna target areas for silencing |
| AU2021416356A1 (en) | 2020-12-28 | 2023-08-10 | 1E Therapeutics, Ltd. | P21 mrna targeting dnazymes |
| CN113633642A (zh) * | 2021-08-26 | 2021-11-12 | 山东第一医科大学附属青岛眼科医院(山东省眼科研究所、青岛眼科医院) | Abt-263在制备抑制角膜移植免疫排斥反应的药物中的应用 |
| WO2023064937A1 (en) * | 2021-10-14 | 2023-04-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Programmable delivery platforms for rna structures |
| WO2023096448A1 (ko) * | 2021-11-29 | 2023-06-01 | 에스케이케미칼 주식회사 | 오바토클락스 대사성 질환 및 섬유화 질환 치료 용도 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| CA2006008C (en) | 1988-12-20 | 2000-02-15 | Donald J. Kessler | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US20020123476A1 (en) | 1991-03-19 | 2002-09-05 | Emanuele R. Martin | Therapeutic delivery compositions and methods of use thereof |
| US6933286B2 (en) | 1991-03-19 | 2005-08-23 | R. Martin Emanuele | Therapeutic delivery compositions and methods of use thereof |
| US6235887B1 (en) | 1991-11-26 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5721138A (en) | 1992-12-15 | 1998-02-24 | Sandford University | Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use |
| US5807718A (en) | 1994-12-02 | 1998-09-15 | The Scripps Research Institute | Enzymatic DNA molecules |
| JP2002518521A (ja) | 1998-06-20 | 2002-06-25 | ワシントン・ユニバーシティ | 医用画像解析、診断および治療のための膜透過性ペプチド錯体 |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| CN1608131A (zh) * | 2001-10-26 | 2005-04-20 | 里伯药品公司 | 治疗胰腺癌的药物 |
| WO2007130604A2 (en) | 2006-05-04 | 2007-11-15 | Baylor Research Institute | Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna |
| AU2007283458A1 (en) * | 2006-08-11 | 2008-02-14 | The Walter And Eliza Hall Institute Of Medical Research | Methods for modulating apoptosis in platelets |
| CN101541379A (zh) * | 2006-08-11 | 2009-09-23 | 沃尔特及伊莱萨霍尔医学研究院 | 用于调控细胞存活的方法 |
| DK2194783T3 (en) * | 2007-08-10 | 2017-10-02 | Vm Discovery Inc | COMPOSITIONS AND PROCEDURES FOR APOPTOS MODULATORS |
| WO2010039668A2 (en) | 2008-10-01 | 2010-04-08 | The Regents Of The University Of California | Inhibitors of cyclin kinase inhibitor p21 |
| US20110020221A1 (en) * | 2009-04-09 | 2011-01-27 | The Johns Hopkins University | Cancer stem cell expression patterns and compounds to target cancer stem cells |
| EP2477972A1 (en) * | 2009-09-20 | 2012-07-25 | Abbott Laboratories | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases |
| CA2825306C (en) * | 2011-01-25 | 2019-02-26 | The Regents Of The University Of Michigan | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
| AR085958A1 (es) * | 2011-04-08 | 2013-11-06 | Afraxis Inc | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del cns y cancer |
| ES2545855T3 (es) * | 2011-06-09 | 2015-09-16 | Isdin, S. A. | Uso de fotoliasa para la reducción o mejora del campo de cancerización subclínico asociado a la queratosis actínica |
| EP2748329B1 (en) * | 2011-11-07 | 2019-04-03 | The Regents of The University of California | Niche targeting of quiescent cancer stem cells |
| WO2014047427A2 (en) * | 2012-09-21 | 2014-03-27 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors |
-
2014
- 2014-04-13 CN CN201480035042.7A patent/CN105377289A/zh active Pending
- 2014-04-13 CA CA2909380A patent/CA2909380A1/en not_active Abandoned
- 2014-04-13 BR BR112015026702A patent/BR112015026702A2/pt not_active IP Right Cessation
- 2014-04-13 MX MX2015014582A patent/MX2015014582A/es unknown
- 2014-04-13 WO PCT/IL2014/050358 patent/WO2014174511A1/en not_active Ceased
- 2014-04-13 US US14/784,312 patent/US20160122758A1/en not_active Abandoned
- 2014-04-13 JP JP2016508288A patent/JP2016516808A/ja active Pending
- 2014-04-13 EP EP14727628.1A patent/EP2988767A1/en not_active Withdrawn
- 2014-04-13 RU RU2015149680A patent/RU2015149680A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516808A5 (OSRAM) | ||
| RU2015149680A (ru) | Агенты для подавления активности и/или снижения количества bcl-xl и/или bcl-w | |
| JP2014516942A5 (OSRAM) | ||
| JP2015078230A5 (OSRAM) | ||
| JP2016528301A5 (OSRAM) | ||
| JP2017504611A5 (OSRAM) | ||
| JP2013509429A5 (OSRAM) | ||
| JP2014505733A5 (OSRAM) | ||
| JP2013542247A5 (OSRAM) | ||
| JP2009102342A5 (OSRAM) | ||
| EP4620525A3 (en) | Methods and compositions for treatment of pulmonary hypertension and other lung disorders | |
| JP2017537936A5 (OSRAM) | ||
| RU2015149527A (ru) | Производные доластатина 10 и ауристатинов | |
| DOP2014000271A (es) | Nueva forma de dosificacion y formulacion de abediterol | |
| JP2015510916A5 (OSRAM) | ||
| JP2015098469A5 (OSRAM) | ||
| JP2015502926A5 (OSRAM) | ||
| MY191712A (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
| JP2020529995A5 (OSRAM) | ||
| JP2014504636A5 (OSRAM) | ||
| JP2016515550A5 (OSRAM) | ||
| JP2020502132A5 (OSRAM) | ||
| JP2014530204A5 (OSRAM) | ||
| JP2014500257A5 (OSRAM) | ||
| JP2011500731A5 (OSRAM) |